The treatment of malaria targets primarily the blood stage ofPlasmodium infection. While chloroquine hasbeen the therapeutic drug of choice, increasing resistance among allPlasmodium spp., particularly P.falciparum, has led to the adoption ofartemisinin-based therapy (Burki, 2011). However, resistanceto artemisinins has nowbeen reported in a growing number of countries in south-east Asia,and WHO recommends that oral artemisinin-based monotherapies bewithdrawn from the market and replaced with artemisinin-basedcombination therapy (WHO,2011).
Yapoo Market Ymd 86 24
2ff7e9595c
Komentarai